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A B S T R A C T
The purpose of this study was to develop the immediate release stomach-specific spray-
dried formulation of valsartan (VAL) using Eudragit® E PO (EPO) as the carrier for enhancing
dissolution rate in a gastric environment. Enhanced solubility and dissolution in gastric pH
was achieved by formulating the solid dispersion using a spray drying technique. Different
combinations of drug–polymer–surfactant were dissolved in 10% ethanol solution and spray-
dried in order to obtain solid dispersion microparticles. Use of the VAL–EPO solid dispersion
microparticles resulted in significant improvement of the dissolution rate of the drug at pH
1.2 and pH 4.0, compared to the free drug powder and the commercial product. A hard gelatin
capsule was filled with the VAL–EPO solid dispersion powder prior to the dissolution test.
The increased dissolution of VAL from solid dispersion microparticles in gastric pH was at-
tributed to the effect of EPO and most importantly the transformation of crystalline drugs
to amorphous solid dispersion powder, which was clearly shown by scanning electron mi-
croscopy (SEM), differential scanning calorimetry (DSC), and powder X-ray diffraction (P-
XRD) studies. Thus,VAL, a potential antihypertensive drug in the form of a solid dispersion
microparticulate powder, can be effectively delivered in the immediate release dosage form
for stomach-specific drug delivery.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This









Approximately 970 million people worldwide have hyperten-
sion and thus are at an increased risk for cardiac events [1].
Notably, hypertension is the most common risk factor for car-
diovascular disease, exceeding diabetes mellitus, obesity,
dyslipidemia, and smoking. Uncontrolled hypertension specifi-
cally leads to increased fatal andnonfatal stroke andmyocardial
infarction, along with heart failure and chronic kidney disease
[2].Antihypertensive therapywith appropriate reduction in blood
pressure has been shown to reduce this increased risk [3,4].
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4-yl] methyl}-L-valine) is a nonpeptide, orally active, specific
angiotensin II antagonist acting on the AT1 receptor subtype.
It is indicated for hypertension, heart failure and post-
myocardial infarction, and is categorized as angiotensin-II
receptor blocker [5,6]. According to the Biopharmaceutical Clas-
sification System (BCS), valsartan is considered a BCS class II
compound with low solubility and high permeability [7–9].
Valsartan is not entirely lipophilic and exhibits pH-dependent
solubility, with solubility of 16.8 g/l and 0.18 g/l in phosphate
buffer solution (PBS) pH 8.0 and water, respectively. Being a
weakly acidic drug (pKa = 4.37), valsartan is generally in the
ionized form at higher pH, and thus has greater solubility [10].
At the lower pH in the stomach, valsartan exists mainly in the
unionized form,which can facilitate permeation, but drug solu-
bility is the limiting factor. Therefore, a well-designed
formulation that improves the solubility and drug release of
valsartan at low pH is desirable for promoting more favor-
able pharmacokinetics of valsartan.
For several decades,methacrylate copolymers with the brand
name Eudragit have been used in oral drug delivery systems
[11,12]. Eudragit® E PO (EPO) dissolves in the gastric pH because
of its basic site containing tertiary amine groups, which are
ionized in gastric fluid [4].
Eudragit® E PO is a cationic copolymer based on
dimethylaminoethyl methacrylate, butyl methacrylate, and
methyl methacrylate, and is basically used in coating and film
forming. In recent years, its use has not been limited to only
coating, but also for the preparation of new formulations in-
cluding microcapsules and nanoparticles to improve the
solubility of poorly water soluble drugs [13,14].
In the current study, the EPO was used as the polymer for
preparation of valsartan-loaded EPO solid dispersion
microparticles, basically meant for an immediate drug release
in the gastric pH condition. The formulations with different
drug/polymer ratio of 1:2, 1:3 and 1:4 were prepared and the
corresponding solid dispersion was obtained by spray-drying
technique. Poloxamer 407, a nonionic polyoxyethylene-
polyoxypropylene copolymer, was used as the surface active
agent in the formulations. Scanning electron microscopy (SEM),
differential scanning calorimetry (DSC), and powder X-ray dif-
fraction (P-XRD) were performed for physical characterization
of the solid dispersion microparticles. The effect of drug/
polymer ratio on the drug dissolution was compared with that
of the free drug powder and the commercial product.
2. Materials and methods
2.1. Materials
Valsartan was supplied by Hanmi Pharm. Co. (Suwon, Korea).
Eudragit® E PO was purchased from Evonik Industries (Darm-
stadt, Germany). Lutrol® F127 (Poloxamer 407) and Pluronic®
F68 (Poloxamer 188) were purchased from BASF Corporation
(Ludwigshafen, Germany). Acetic acid was purchased from DC
Chemical Co., Ltd. (Namyangju, Korea). Sorbitan monolaurate
20 (Span 20), sorbitan monooleate 80 (Span 80), polysorbate 20
(Tween 20), and polysorbate 80 (Tween 80) were purchased from
Duksan Chemical Co. (Ansan, Korea). The commercial product
(Diovan®; in a tablet form) was purchased from the market. All
other chemicals were of reagent grade and were used without
further purification.
2.2. Solubility study in various surfactants
An excess of valsartan powder (about 1 g) was added to 10 ml
of 10% of the carrier, as shown in Table 1. Excess amounts of
the solid dispersions (about 1 g) were added to 10 ml of water,
followed by shaking in a water bath at 25 °C for 3 days, and
then centrifuged at 3000 × g for 10 min (Eppendorf, USA) and
filtered through a membrane filter (0.45 μm). HPLC was per-
formed for analysis of the concentration of valsartan in the
resulting solution, as described below.
2.3. Preparation of valsartan-loaded EPO solid dispersion
microparticles
Valsartan-loaded EPO solid dispersion microparticles were pre-
pared using a lab-scale Buchi 191 nozzle-type mini spray dryer
(Flawil, Switzerland). Then, 0.5 g of pre-sieved valsartan and
various amounts of Eudragit EPO in the drug–polymer ratio of
1:2, 1:3, and 1:4 was dissolved in 20 ml of ethanol, while various
amounts of poloxamer 407 at the constant ratio of 1:2
(poloxamer 407:Eudragit E PO) were dissolved in 180 ml water.
Subsequently, valsartan–EPO solution was dispersed in the
poloxamer 407 solution under magnetic stirring with the ad-
dition of 0.2 ml of acetic acid, which gave a fine homogenous
clear solution. Details on the compositions of the valsartan–
EPO solid dispersion are shown in Table 2. The resulting clear
solutions were immediately spray-dried. The inlet and outlet
temperatures were 120 °C and 65–70 °C, respectively. The flow
rate was maintained at the speed of 3 ml/min using a peri-
staltic pump. The spray-pressure was 4 kg/cm2. Atomization
of the drying air was maintained at an aspirator setting of 10,
indicating that the pressure in the aspirator vessels was
−25 mbar.The direction of air flow was the same as that of the
sprayed products [15,16].
Table 1 – Solubility of valsartan in various surfactants.
Surfactants Aqueous solubility of
valsartan (μg/ml)
Poloxamer 188 504.1 ± 105.7
Poloxamer 407 839.3 ± 71.1
Span 20 80.0 ± 18.0
Span 80 27.3 ± 6.7
Tween 20 418.1 ± 17.4
Tween 80 624.8 ± 56.3
Each value indicates the solubility of valsartan in distilled water con-
taining 10% surfactant (mean ± S.E., n = 3).
Table 2 – Formulations of valsartan-loaded Eudragit-EPO
solid dispersion microparticles.
Formulations F-1 F-2 F-3
Valsartan 0.5 0.5 0.5
Eudragit-E PO 1.0 1.5 2.0
Poloxamer 407 0.5 0.75 1.0
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2.4. Determination of drug content
Appropriate weight of valsartan–EPO solid dispersion
microparticles equivalent to 50 mg valsartan was dissolved in
50 ml methanol and diluted appropriately to obtain a final con-
centration of 100 μg/ml. The samples were analyzed by HPLC
method. The drug content of the solid dispersions was deter-
mined in triplicate.
2.5. HPLC conditions
As reported previously, the HPLC system was composed of a
Hitachi HPLC system consisting of a pump (Model L2100), an
auto sampler (Model L2200), and an ultraviolet detector (Model
L2420). A C18 analytical column (Inertsil® ODS-3, 5 μm,
0.46 cm ×15 cm, GL Sciences Inc., Japan) was used.The mobile
phase consisted of a mixture of HPLC grade acetonitrile (ACN)
and purified water (60:40 v/v), and the pH was adjusted to pH
3.0 with 10% phosphoric acid, and it was filtered under vacuum
and degassed before use.The standard and test samples were
monitored at a UV absorption wavelength of 247 nm and a flow
rate of 1.0 ml/min [17–19]. All experiments were performed in
triplicates.
2.6. Solid state characterization
2.6.1. Scanning electron microscopy (SEM)
Morphological analysis was performed using an S-4100 scan-
ning electron microscope (SEM) (Hitachi,Tokyo, Japan).The SEM
photomicrographs were taken for comparison of the morphol-
ogy of pure valsartan powder, Eudragit E PO powder, poloxamer
407, and the valsartan–EPO solid dispersion microparticles.The
samples were fixed on a brass-stub using double-sided adhe-
sive tape and made electrically conductive by coating in a
vacuum (6 Pa) with platinum (6 nm/min) using a Hitachi Ion
Sputter (E-1030) for 120 s at 15 mA.The SEM images were ana-
lyzed using an image analysis system (ImageInside Ver 2.32).
2.6.2. Differential scanning calorimetry (DSC)
The thermal analyses of pure valsartan powder, Eudragit EPO
powder, poloxamer 407, and the valsartan–EPO solid disper-
sion microparticles were performed using differential scanning
calorimetry (DSC Q200 v24.2 build 107, TA Instruments, New
Castle, DE, USA). The samples (about 1.50 mg) were placed in
standard aluminum pans, and dry nitrogen was used as ef-
fluent gas. All samples were scanned at a temperature ramp
speed of 10 °C/min and the heat flow from 40 to 350 °C.
2.6.3. Powder X-ray diffraction (P-XRD)
The P-XRD patterns of pure valsartan powder, Eudragit EPO
powder, poloxamer 407, and the valsartan–EPO solid disper-
sion microparticles were measured using the X’Pert PRO
diffractometer (PAN analytical, Netherlands) at room tempera-
ture using monochromatic Cu Kα-radiation (γ = 1.5406A´˚) at
30 mA and 40 kV over a range of 2θ angles from 10° to 50° with
an angular increment of 0.02°/s.
2.7. In vitro dissolution study
Hard gelatin capsules, ‘0’ size (Suheung capsule Co. Ltd., Seoul,
South Korea), were filled with the accurately weighed valsartan–
EPO solid dispersion microparticles equivalent to 40 mg of
valsartan.The dissolution test was performed at 36.5 °C using
the US Pharmacopoeia dissolution apparatus 1 (basket method)
at 50 rpmwith 900ml of hydrochloric acid buffer pH 1.2, acetate
buffer pH 4.0, and phosphate buffer pH 6.8 as the dissolution
media; 1 ml of dissolution samples was withdrawn at 0, 5, 15,
and 30 min, followed by addition of an equal volume of fresh
dissolutionmedia maintained at the same temperature in order
to keep the volume of dissolution media constant and to main-
tain the sink condition [20,21]. The withdrawn samples were
filtered through a syringe filter (0.45 μm) and analyzed using
HPLC.
2.8. Data analysis and statistical evaluation
All experiments were performed at least three times and the
data were expressed as the mean ± standard deviation (S.D.).
Levels of statistical significance (P < 0.05) were assessed using
the Student t-test between two means for unpaired data using
Microsoft Office Excel 2007.
3. Results and discussion
3.1. Solubility study in various surfactants
For selection of a suitable surfactant for preparation of
valsartan–EPO solid dispersion microparticles, the solubility of
valsartan in distilled water containing 10% of various surfac-
tants was assessed (Table 1). Among the surfactants tested,
poloxamer 407 showed the highest solubility of valsartan,which
was approximately 800 μg/ml. Poloxamer 407, known as Lutrol
or Pluronic F127, is a hydrophilic non-ionic surfactant used
widely in pharmaceutical formulations due to its low toxicity
and solubilizing ability. Thus, poloxamer 407 was selected as
the surfactant for the development of the valsartan–EPO solid
dispersion microparticles.
3.2. Preparation of valsartan–EPO solid dispersion
microparticles
Valsartan–EPO solid dispersion microparticles were prepared
using a spray drying technique.The schematic diagram of the
preparation of valsartan–EPO solid dispersion microparticles
is shown in Fig. 1. Briefly, EPO and valsartan at various ratios
of 1:2, 1:3, and 1:4 corresponding to formulations F-1, F-2, and
F-3, respectively, were dissolved in 20 ml ethanol, while
poloxamer 407 was dissolved in 180 ml of water.The ethanolic
solution was slowly poured into water containing poloxamer
407 with continuous stirring. To obtain a clear solution, 0.2 ml
of acetic acid was added dropwise to the hydro-alcoholic
solution, which provided an acidic environment, so that
EPO dissolved along with valsartan. Due to the presence of
poloxamer 407, the solubility of valsartan in the resultant hydro-
alcoholic solution was increased so that the clear solution was
obtained.The solution was immediately spray-dried to obtain
the white valsartan–EPO solid dispersion microparticulate
powder. The results of analysis for the drug content (%) con-
sidering the quantity of powders equivalent to 50 mg valsartan
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were 100.7%, 99.5%, and 99.2 % for formulations F1, F2, and F3,
respectively.
3.3. Solid state characterization of valsartan–EPO solid
dispersion microparticles
Various tests including SEM analysis, DSC measurements, and
P-XRD calorimetry were performed for the solid state charac-
terization of valsartan–EPO solid dispersion microparticles.The
morphology of the representative SEM images of the valsartan
powder, Eudragit E PO, poloxamer 407, and valsartan–EPO solid
dispersionmicroparticles (formulation F-1, F-2 and F-3) is shown
in Fig. 2.The SEMmicrographs of the valsartan powders (Fig. 2A)
showed irregular-shaped crystalline particles, whereas Eudragit
EPO and poloxamer 407 (Fig. 2B and 2C) were observed as amor-
phous smooth particles. On the other hand, formulations F-1,
F-2 and F-3 were spherical in shape with smooth morphol-
ogy and particle size than 5 μm, as shown in Fig. 2D, 2E, and
2F. However, among the three formulations, F-2 showed good
particle size distribution with relatively more uniform size and
spherical morphology, which may be attributed to the optimum
weight ratio of the valsartan/Eudragit EPO/poloxamer 407 of
0.5/1.5/0.75.
The DSC thermographs of valsartan powder, Eudragit EPO,
poloxamer 407, and valsartan–EPO solid dispersion
microparticles are shown in Fig. 3. Valsartan powder showed
the characteristic single sharp endothermic peak at approxi-
mately 110 °C, corresponding to its melting point and crystalline
nature. No distinct peaks were observed for Eudragit EPO in
the range of 40–150 °C. The broad endothermic peak of
poloxamer 407 was observed at approximately 50 °C, while no
peak was observed in the case of valsartan–EPO solid disper-
sion microparticles corresponding to the strong molecular
dispersion between the valsartan and the Eudragit EPO.
Fig. 1 – Schematic diagram of preparation of valsartan-loaded Eudragit E PO microparticles.
Fig. 2 – Scanning electron micrographs of (A) Eudragit E PO, (B) valsartan powder, (C) Poloxamer 407, (D) F-1, (E) F-2, and (F)
F-3.
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However, a small peak corresponding to that of poloxamer 407
was observed in all formulations with the intensity propor-
tional to the increase in the poloxamer 407 content.
The powder X-ray diffractometry pattern of VAL showed in-
trinsic peaks at the diffraction angles, showing a typical
crystalline pattern (Fig. 4). No intrinsic peaks were observed
in the case of Eudragit EPO, but poloxamer exhibited two sharp
peaks at the angles between 15° and 25°. Formulations F-1~F-3
showed the characteristic peaks of poloxamer 407, but of
reduced intensity proportional to the amount of the poloxamer
407 present in the formulations. Thus, both the DSC and the
XRD results demonstrated that valsartan strongly interacted
with both Eudragit EPO and poloxamer 407 and was trans-
formed itself into the molecularly dispersed form, which was
obtained as the valsartan–EPO solid dispersion microparticles.
3.4. In vitro dissolution study
The in vitro dissolution study of valsartan–EPO solid disper-
sion microparticles, free drug powder and the commercial
product was performed in hydrochloric acid buffer pH 1.2,
acetate buffer pH 4.0, and phosphate buffer pH 6.8. As shown
in Fig. 5, the % release of valsartan from the valsartan–EPO solid
dispersionmicroparticles in hydrochloric acid buffer pH 1.2 was
almost 100% in 15 min, while that of free valsartan powder and
the commercial product were less than 1.0% in 15 min. The %
release of valsartan from the valsartan–EPO solid dispersion
microparticles in acetate buffer pH 4.0 was almost 100% in
30 min, while that of free valsartan powder and the commer-
cial product were less than 1.0% in 30 min (Fig. 6).The % release
of valsartan from the valsartan–EPO solid dispersion
microparticles in phosphate buffer pH 6.8 was almost 20%,while
that of free valsartan powder and the commercial product were
more than 28% and 90%, respectively, in 30 min. The absorp-
tion window of valsartan is basically in the region of the
stomach, because it is largely present in a unionized form in
the acidic pH and better absorbed from the acidic pH of the
stomach than the basic pH condition of the intestine which
can facilitate permeation; however, drug solubility is the lim-
iting factor [9,22]. Our results clearly demonstrated that the
release of valsartan was specifically completed in the gastric
region (pH ranging from 1.2 to 4.0) corresponding to the
enhanced solubility of valsartan using Eudragit E PO as the
solid dispersion carrier. Therefore, use of valsartan–EPO solid
dispersion microparticles as the delivery system for the im-
mediate release of valsartan in the gastric environment was
advantageous, leading to rapid absorption and immediate phar-
macological action (Fig. 7).
Fig. 3 – Differential scanning calorimetric thermograms of
valsartan powder, Eudragit E PO, poloxamer 407, F-1, F-2,
and F-3.
Fig. 4 – Powder X-ray diffractometry patterns of valsartan
powder, Eudragit E PO, poloxamer 407, F-1, F-2, and F-3.
Fig. 5 – In vitro dissolution profiles of valsartan powder,
formulations F-1, F-2, F-3, and commercial product at
hydrochloric acid buffer pH 1.2. Each value represents the
mean ± standard deviation (n = 3).
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4. Conclusion
In this study, the immediate release valsartan–EPO solid dis-
persionmicroparticles was developed by spray drying technique.
The solid-state characterization such as SEM, DSC, and P-XRD
studies clearly demonstrated smooth spherical morphology and
strong molecular dispersion between valsartan, Eudragit EPO
and poloxamer 407. In addition, valsartan–EPO solid disper-
sion microparticles exhibited an immediate release dissolution
profile in pH 1.2 and pH 4.0, compared with the free valsartan
powder. Therefore, the developed formulation with immedi-
ate drug release profile could be an effective drug delivery
system in the treatment of hypertension.
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